Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 3,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: T cells Clear all

Conditions: HER2-positive Breast Cancer
Interventions: Dendritic Cell (DC1) Vaccine, Trastuzumab, Pepinemab, T-Cell therapy; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Lymphoma, Radiation Toxicity
Interventions: pentetic acid calcium, yttrium Y 90 daclizumab; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Interventions: lisocabtagene maraleucel; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 59
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 19 more

Conditions: Nasopharyngeal Carcinoma
Interventions: Genetically modified CTLs; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Leukemia, Lymphoma
Interventions: HSCT, DLI; Procedure · Genetic
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions: Azacitidine, Cytarabine, Fludarabine Phosphate, Methotrexate, Pevonedistat, Therapeutic Hydrocortisone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Month to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 19
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 16 more

Conditions: Solid Tumor
Interventions: High-Dose Conformal Radiation Therapy, Pembrolizumab; Radiation · Drug
Lead sponsor: James Larner, MD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Interventions: STAR0602, Sacituzumab Govitecan (SG); Drug
Lead sponsor: Marengo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • Columbus, Ohio + 2 more

Conditions: Metastatic Solid Tumor
Interventions: TAC01-CLDN18.2; Biological
Lead sponsor: Triumvira Immunologics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 4 more

Conditions: Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions: Specific T- Lymphocytes; Biological
Lead sponsor: Paul Szabolcs; Other
Eligibility: 1 Month to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions: Ara-C, Mitoxantrone, Etoposide; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 10 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer
Interventions: Laboratory Biomarker Analysis; Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer
Interventions: caspofungin acetate, liposomal amphotericin B; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Neoplasm
Interventions: aldesleukin, incomplete Freund's adjuvant, p53 peptide vaccine, sargramostim, therapeutic autologous dendritic cells, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alveolar Bone Loss
Interventions: Tissue Repair Cells (TRC), Control; Biological · Device
Lead sponsor: University of Michigan; Other
Eligibility: 20 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Relapsed and Refractory Multiple Myeloma
Interventions: anitocabtagene-autoleucel; Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Milwaukee, Wisconsin

Conditions: Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy, Lymphoma, Cell Therapy
Interventions: Exercise, Isoproterenol, Placebo, Bisoprolol Fumarate Tablet 10 mg, Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Carvedilol 50 mg, Roflumilast 500 Mcg Oral Tablet; Behavioral · Drug
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years to 55 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2031
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: B-cell Acute Lymphoblastic Leukemia
Interventions: UCART19; Biological
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 16 Years to 69 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas

Conditions: B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent, High Grade B-Cell Lymphoma-Recurrent, Primary Mediastinal Large B-Cell Lymphoma-Recurrent, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory, Diffuse Large B-Cell Lymphoma-Refractory, Follicular Lymphoma-Refractory, High Grade B-Cell Lymphoma-Refractory, Primary Mediastinal Large B-Cell Lymphoma-Refractory, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Golcadomide, Positron Emission Tomography, Rituximab; Procedure · Drug · Biological
Lead sponsor: Nathan Denlinger; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions: Cytarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Prexasertib; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma, Non-Hodgkin
Interventions: Fludarabine, Cyclophosphamide, JCAR017; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 23
States / cities: Santa Monica, California • Aurora, Colorado • New Haven, Connecticut + 18 more

Conditions: CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
Interventions: Hypericin, Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 17
States / cities: Phoenix, Arizona • Scottsdale, Arizona • San Diego, California + 14 more

Conditions: Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Transformed Mycosis Fungoides
Interventions: Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Scottsdale, Arizona • Duarte, California • Atlanta, Georgia

Search by objective public record fields.

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

Monoclonal Antibody Therapy in Treating Patients With Leukemia

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

HDCRT Plus Pembrolizumab in Advanced Malignancies

In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

Anti-viral T-cell Therapy by Gamma Capture

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

p53 Vaccine for Ovarian Cancer

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma